HPR45 Impact of Nilotinib Reimbursement Coverage on the Use of Tyrosine Kinase Inhibitors (TKI) for Chronic Myeloid Leukemia (CML) in Chinese Tertiary Care Hospitals: A Retrospective Analysis
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.971
https://www.valueinhealthjournal.com/article/S1098-3015(22)01172-X/fulltext
Title :
HPR45 Impact of Nilotinib Reimbursement Coverage on the Use of Tyrosine Kinase Inhibitors (TKI) for Chronic Myeloid Leukemia (CML) in Chinese Tertiary Care Hospitals: A Retrospective Analysis
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)01172-X&doi=10.1016/j.jval.2022.04.971
First page :
Section Title :
Open access? :
No
Section Order :
10875